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http://dx.doi.org/10.1016/j.jmii.2012Objective: To delineate whether serotype 19A invasive pneumococcal disease (IPD) comprised
significantly more necrotizing pneumonia and empyema in children, we compared the clinical
characteristics between serotype 19A and non-19A IPD.
Methods: Between January 2007 and December 2011, cases of children with IPD who were
treated at the National Taiwan University Hospital were reviewed. Patients were assigned to
the 19A group or the non-19A group based on the serotype. Their demographic data, clinical
course, laboratory results, diagnosis, complications, and sequelae were collected and
analyzed.
Results: Overall, 27 patients were included in the 19A group and 29 patients in the non-19A
group. Compared with non-19A group, serotype 19A tended to cause IPD in patients without
major underlying diseases (p Z 0.015). Bacteremia without pneumonia or meningitis was
found more frequently in the non-19A group (45% vs. 11%, p Z 0.01), and pneumonia with
or without empyema occurred significantly more frequently in the 19A group (89% vs. 52%,
p Z 0.006). Patients in the19A group had longer duration of fever (12 vs. 3 days, p Z 0.01),
and required more intensive care (78% vs. 41%, p Z 0.01) and more video-assisted thoraco-
scopic surgery (74% vs. 28%, p Z 0.001).of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University,
, Taiwan.
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24 C.-Y. Lai et al.Conclusion: In comparison with the other serotypes, serotype 19A IPD has significantly more
empyema which required more video-assisted thoracoscopic surgery and more intensive care.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Invasive pneumococcal disease (IPD) is a very important
disease in children and may cause significant morbidity and
even fatality. Since seven-valent pneumococcal conjugate
vaccine (PCV7) was launched, the incidence of IPD
dramatically decreased in countries with nationwide
immunization programs.1,2 However, the incidence of
certain serotypes which were not covered by PCV7
increased significantly later on. The most common is the
serotype 19A Streptococcus pneumoniae, which was
observed to increase in incidence in United States.3,4
In Taiwan, PCV7 was launched in October 2005, and it
was self-paid vaccine, not covered by the national immu-
nization program. The coverage rate of PCV7 among
Taiwanese children aged 5 years was 0.7% in 2005, 8.6% in
2006, 15.9% in 2007, and 25.2% in 2008.5 Although the
coverage rate of PCV7 was not high in Taiwan, we also
observed the rising incidence of serotype 19A IPD in
Taiwan.6 In addition, we found that the proportion of
necrotizing pneumonia and empyema was high in cases with
serotype 19A IPD. To delineate whether serotype 19A IPD
would cause significantly more necrotizing pneumonia and
empyema, we thus compared the clinical characteristics
between serotype 19A and non-19A IPD.Methods
Patient collection
IPD was defined when S. pneumoniae were recovered from
a normally sterile site such as blood, pleural effusion,
cerebrospinal fluid, or ascites by culture or polymerase
chain reaction (PCR).7 Between January2007 and December
2011, data on pediatric patients under 18 years with IPD in
National Taiwan University Hospital were collected.Clinical data collection
Patients were assigned to the 19A group or the non-19A
group based on the serotype. Data pertaining to medical
records, demographic details, clinical course, laboratory
results, diagnosis, and complication of these patients were
collected and analyzed. Respiratory failure was defined as
the need for positive pressure ventilation. Pneumonia
among patients of IPD was further looked up to find the
presence of empyema, or necrotizing pneumonia.
Empyema was defined as the presence of pus in pleural
space diagnosed by pleurocentesis or video-assisted thor-
acoscopic surgery (VATS),8 and necrotizing pneumonia was
defined as multiple small radiolucency or pneumatocele ona chest radiograph or as cavities of non-enhancement on
a contrast-enhanced CT image.9
Microbiological study
Antibiotic sensitivity was reported by disk-diffusion method
and minimal inhibitory concentration tested using E-test.
The interpretation was categorized according to the 2011
Clinical and Laboratory Standards Institute guidelines for
breakpoints.10
Pneumococcal isolates were identified by the recogni-
tion of typical colony morphology on trypticase soy agar
supplemented with 5% sheep blood (BBL Microbiology
Systems, Cockeyville, MD, USA), Gram stain characteristics,
susceptibility to ethylhydrocupreine hydrochloride (Opto-
chin; Difco Laboratories, Detroit, MI, USA), and bile solu-
bility. The isolate’s serotype was determined with latex
agglutination (Pneumotest-Latex, Statens Serum Instuit,
Copenhagen, Denmark).
Using blood and/or pleural effusion, PCR was per-
formed optionally according to the primary care physi-
cian’s clinical suspicion. Total nucleic acid was extracted
from pleural effusion or blood specimens. Real-time PCR
targeting the wzg gene was first performed to confirm the
presence of S. pneumoniae DNA as previously reported.11
Positive samples were included in the serotyping analysis
by target gene PCR subsequently. Serotyping of serogroup
6 and serogroup 15 could only be done via latex aggluti-
nation but not PCR in our laboratory. Thus, some samples
with positive PCR but negative culture only had serogroup
recognized.
Statistics
Chi-square test with Yate’s correction was used to compare
the categorical data between the 19A and non-19A groups.
Student’s t-test was used to compare age and
ManneWhitney test was used for comparison of duration
and laboratory data such as peak C-reactive protein level
between the 19A and non-19A groups. A p value < 0.05 was
considered statistically significant. All analyses were per-
formed with SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Cases
Overall, 27 patients were included in the 19A group and 29
patients in the non-19A group. The non-19 A group
comprised serotype 3 (4 patients), serogroup 6 (1 patient),
serotype 6A (2 patients), serotype 6B (2 patients), serotype
14 (4 patients), serogroup 15 (2 patients), serotype 15B
Table 1 Comparison of demographic characteristics






Male/female 16:11 14:15 0.58
Age (mean  SD) 3.95  1.39 4.28  2.67 0.57
Kindergarten or daycare
or school attendance
60% (15/25) 54% (15/28) 0.74
Major underlying disease 11% (3/27)a 41% (12/29)b 0.015
PCV7 vaccinated 52% (12/25) 43% (12/28) 0.70
PCV7 Z pneumococcal seven-valent conjugate vaccine.
a One patient had complex congenital heart disease, one had
rhadomyosarcoma, and another patient had chromosome
anomaly (47, XXX).
b There were four biliary atresia, three complex congenital
heart disease, two severe aplastic anemia, one acute lympho-
blastic leukemia, one methyl malonic academia, and one airway
anomaly.
Invasive pneumococcal disease in children 25(3 patients), serotype 18C (1 patient), serotype 19F
(9 patients), and serotype 23F (1 patient). No blood sample
yielded positive PCR result. Eleven pleural effusion samples
had positive PCR results but negative culture results. The
yearly distribution of 19A and non-19A groups is shown in
Fig. 1. The case number of 19A IPD tends to increase year
by year (p Z 0.09), especially in the year 2011.
Demography
Table 1 shows the demographic characteristics of the two
groups. The mean age was about 4 years in both, groups and
the PCV7 vaccinated rate was 52% in 19A group and 43% in
non-19A group. Compared with the non-19A group,
S. pneumoniae serotype 19A tended to cause IPD in patients
without major underlying diseases (Table 1, p Z 0.015).
Other demographic features were similar between the two
groups.
Diagnosis
Bacteremia without pneumonia or meningitis was found
more frequently in the non-19A group (p Z 0.01). Most
cases of bacteremia without pneumonia or meningitis had
otitis and/or mastoiditis or sinusitis. Non-19A tended to
have more occult bacteremia than the 19A group
(pZ 0.07). The 19A group accounted for significantly more
pneumonia (pZ 0.006) and empyema (p < 0.001) (Table 2).
Clinical course
The 19A group had longer duration of fever (12 vs. 3 days,
p Z 0.01) and higher peak C-reactive protein level (27.36
vs. 8.19 mg/dL, p < 0.001) than the non-19A group
(Table 3). The ratio of leukocytosis, leucopenia, and
thrombocytopenia did not differ significantly between the
two groups. Although the incidence of respiratory failure,
shock, and hemolytic uremic syndrome was not significantly
different between two groups, patients of the 19A group
were more often admitted to the intensive care unit. VATS
was performed more frequently in patients of the 19A
group (p Z 0.001).Figure 1. Yearly distribution of invasive pneumococcal
disease caused by 19A serotype and non-19A serotype in
2007e2011.Outcome
Table 4 shows the final outcome and complication between
two groups. There was one fatal patient in each group, and
the mortality rate of the two groups was similar. Compli-
cations occurred in a similar ratio in both groups (15% in 19A
group and 11% in non-19A group, p Z 0.92) and only
occurred in cases with necrotizing pneumonia. The
complications included pneumatocele (6 patients), bron-
chopulmonary fistula (3 patients), and pneumothorax (3
patients). No patient received urokinase therapy.
Antimicrobial sensitivity
Disk method was used to define the sensitivity to erythro-
mycin, moxifloxacin, levofloxacin, clindamycin, tetracy-
cline, chloramphenicol, tigycycline, and vancomycin.
There was no statistically significant difference between
the two groups for the drugs discussed above. E-test was
used to obtain the minimum inhibition concentration of
penicillin, cefotaxime, vancomycin, and levofloxacin. The
19A group seemed to be less sensitive to cefotaxime than
the non-19A group [6% (1/18) for 19A group, 32% (6/19) for
non-19A group, p Z 0.09]. Sensitivity to penicillin [53%
(10/19) for 19A group, 63% (12/19) for non-19A group],
levofloxacin [88% (7/8) for 19A group, 100% (2/2) for non-
19A group], and vancomycin [100% (12/12) for 19A group,
100% (8/8) for non-19A group] were not significantly
different between the two groups.
Discussion
We found that the case number of serotype 19A IPD
increased in Taiwan after 2008 (Fig. 1). Empyema and
necrotizing pneumonia occurred more frequently in sero-
type 19A IPD than in the non-19A group. Therefore, cases of
19A IPD had significantly longer hospitalization, and
required significantly more intensive care and VATS.
After the launch of PCV7, the incidence of vaccine-type
IPD markedly decreased.1,2 Later on, serotype replacement






Fever 100% (27/27) 100% (29/29) NS
Duration, median (range) 12 d (3e39) 3 d (1e53) 0.01
Peak C-reactive protein (mg/dL) 27.36 (1.25e60.5) 8.19 (0.05e37.9) <0.001
Respiratory failure 26% (7/27) 21% (6/29) 0.88
Shock 15% (4/27) 14% (4/29) 0.88
Hemolytic uremic syndrome 7% (2/27) 10% (3/29) 0.79
Hospitalization 96% (26/27) 97% (28/29) 0.93
Duration, median (range) 16.5 (7e71) 12 (1e156) 0.08
ICU care 78% (21/27) 41% (12/29) 0.01
Duration 5.5 (2e62) 4 (1e142) 0.42
VATS 74% (20/27) 28% (8/29) 0.001
ICU Z intensive care unit; VATS Zvideo-assisted thoracoscopic surgery; NS Z not significant.






Bacteremia without pneumonia or meningitis 11% (3/27)a 45% (13/29)b 0.01
Occult bacteremia 4% (1/27) 24% (7/29) 0.07
Bacteremia with otitis, mastoiditis, or sinusitis 7% (2/27) 21% (6/29) 0.30
Pneumonia 89% (24/27) 52% (15/29) 0.006
Necrotizing pneumonia 33% (9/27) 14% (4/29) 0.16
Empyema 81% (22/27) 31% (9/29) <0.001
Meningitis 0 3% (1/29) 0.96
a One patient had concurrent acute otitis media and acute otitis externa, another patient had chronic sinusitis, and one had occult
bacteremia.
b Three patients had concurrent acute otitis media, and one patient had acute otitis media and acute mastoiditis. One patient had
acute sinusitis, and another patient had chronic sinusitis and mastoiditis. The other seven had occult bacteremia.
26 C.-Y. Lai et al.was founddthat is, IPD caused by non-vaccine serotype S
pneumoniae increased. The most commonly reported
serotype is 19A.3,4 Taiwan as well as other countries are
faced with the same serotype.5,6 Besides PCV7 selective
pressure, an earlier study proposed that antibiotic use
contributed to the emergence of serotype 19A in Taiwan.6
PCV13 broadens the serotype coverage including 19A, so
we recommend PCV13 to be implemented in Taiwan’s
national immunization program in the future. Continuous
monitoring of IPDepidemiology is still necessary since further
serotype replacement (not covered by PCV13) may occur.
The non-19A group in this study includes serotype 3, 6A, 6B,
14, 15B, 18C, 19F, 23F, and serogroup 6, 15. Most of theseTable 4 Clinical outcome between 19A and non-19A
groups
19A Non-19A p
Mortality 4% (1/27) 3% (1/29) 0.50
Complete recovery 81% (22/27) 86% (25/29) 0.91
Complication 15% (4/26) 11% (3/28) 0.92
Pneumatocele 15% (4/27) 7% (2/28) 0.63
Bronchopulmonary
fistula
4% (1/27) 7% (2/28) 0.97
Pneumothorax 4% (1/27) 7% (2/29) 0.95serotypes could be prevented by PCV13 (except serogroup
15). PCV13was released in April 2011 in Taiwan, andwe hope
that increased PCV13 coverage rate in the future will
decrease the incidence of pediatric IPD in Taiwan.
Different serotypes of S pneumoniae may have different
clinical severity. Seorotypes 1 and 3 had been reported to
be associated with the development of empyema and
necrotizing pneumonia.12,13 In Taiwan, necrotizing pneu-
monia and empyema were associated with serotype 14
before PCV7 was introduced.9 After the introduction of
PCV7, in spite of the decreased incidence of IPD, an
increase in the incidence of empyema was observed.12,14
Serotypes 1, 3, and 19A played important roles in this
suppurative complication in children.14 In this study, we
found that serotype 19A also caused longer fever duration,
higher C-reactive protein, as well as significantly more
empyema, which required more intensive care and VATS
than the other serotypes of pneumococci. Hsieh et al6,15,16
also reported that serotype19A was strongly associated
with high invasive potential and severe necrotizing pneu-
monia and bronchopleural fistula. In contrast, non-19A
groups tends to have bacteremia without pneumonia/
meningitis, and most cases had otitis-origin infection or
occult bacteremiain our study.
In conclusion, serotype 19A IPD accounted for more
severe pneumonia such as empyema, which requires more
Invasive pneumococcal disease in children 27intensive care and thoracic surgery. The high prevalence of
serotype 19A among IPD in Taiwan indicates the serotype
replacement after PCV7 and the importance of 19A inclu-
sion in PCV13 for serotype 19A IPD prevention.
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